Quadria Capital closes oversubscribed $1 bn fund III to advance healthcare across Asia
This latest fundraise is around 60 per cent larger than the firm’s previous $600 million fund raised in 2020
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Market
Biocon Biologics, Yoshindo launch Ustekinumab biosimilar in Japan
Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA)
Cipla launches ZEMDRI (Plazomicin) in India, aims to tackle AMR
Plazomicin is a novel anti-microbial with demonstrated activity against multi-drug resistant (MDR) bacteria and clinical efficacy…
Barentz acquires Fengli, China, aims to strengthen market presence
The partnership would further enhance the service and commercial capabilities of Barentz in China while enabling Fengli Group to…
Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD:…
GlobalData’s latest analysis reveals that tezepelumab, evaluated in the Phase IIa COURSE trial, achieved a 26 per cent reduction…
US drug pricing order – Implications for India’s pharma sector
Ravi Shah, Partner, Cyril Amarchand Mangaldas explains that while the policy is designed to cut costs for US patients, its effects…
Gene therapies drive growth of genomics market, says GlobalData
GlobalData’s latest report reveals that the market for genomic therapies is demonstrating significant growth, with sales projected…
Accretion Pharmaceuticals’ IPO opens for subscription, price band set at ₹96-101 per share
Company also raises ₹2.13 crore from Anchor investors
ATMF report reveals that insulin remains out of reach for T1D patients in LMICs, children facing…
ATMF report recommends practical solutions whereby companies can bring about the fundamental shift that is required to scale up…
Trump calls for drug price cuts, order aims to reduce prices by 30-80 per cent
The order gives drugmakers price targets in the next 30 days, and will take further action to lower prices if those companies do…
Accretion Pharmaceuticals’ IPO to open on May 14 2025; Price band fixed at ₹96-101
The company aims to utilise the funds towards purchasing new equipment, upgrading the manufacturing plant and repayment of certain…
HIV market to exceed $32 bn across 7MM in 2033, forecasts GlobalData
Market growth will primarily be driven by the increased uptake of long-acting injectable therapies, as well as the anticipated…
Pharma CRDMO revenue forecasts 13-15 per cent growth amid supply-chain derisking
Resultant strong cash flows will enable Indian CRDMOs to continue capital expenditure (capex), with limited reliance on debt…
Bionova Scientific licenses ATUM’s proprietary transposon-based gene delivery technology
When used in a cell line development program, Leap-In Transposase technology delivers productive, stable, and robust cell lines,…
Three CAR-T therapies forecasted to capture over 70 per cent of T-Cell immunotherapy market in 2025
GlobalData’s latest report reveals that the TCI space is entering a new growth phase, driven by clinical success and investor…
GLP-1R agonists can redefine chronic disease treatment beyond diabetes and obesity
GlobalData’s latest report showcases an analysis of the GLP-1R agonists pipeline in multiple indications, highlighting the areas…
Biocon Biologics gains market access coverage for Yesintek in the US
Yesintek is a biosimilar to Stelara (ustekinumab) and is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque…
Cell and gene therapy market projected to grow at 31.3% CAGR through 2030
Significant advancements in treatments for dermatology disorders are anticipated, driven by innovations from both small to…
Pharma M&A deal value surges by 101% in Q1 2025 despite US political turbulence
According to GlobalData’s report, oncology remains the leading therapeutic area in Q1 2025, with most of the deals targeting…
Pharma and healthcare deals in Q1 2025 remain stable amid shift to scalable global models
Grant Thornton Bharat reports 71 transactions totalling USD 2.6 billion in Q1 2025, with investor activity focused on mid-market…